乙肝新药

Livewellnyc

澳大利亚研究人员通过使用一种美国研发的治疗癌症的药物，可百分之百治疗乙肝新药

New drug ‘100 percent successful’ in treating previously incurable hepatitis B
Published time: April 22, 2015 19:53
Edited time: April 24, 2015 08:28

Australian scientists have used an experimental cancer drug to completely cure hundreds of mice suffering from chronic hepatitis B. The treatment is now being trialed on humans, and could be used to cure diseases like HIV and drug-resistant tuberculosis.

“We were 100 per cent successful in curing HBV (hepatitis B virus) infection in hundreds of tests in preclinical models,” said Marc Pellegrini, who led a team at Melbourne’s Walter and Eliza Hall Institute, Australia’s oldest medical research facility.

The team, whose findings were published in Proceedings of the National Academy of Sciences (PNAS) journal this week, used birinapant, a US-created cancer drug, which has been trialed on over 350 Americans, but has yet to go on sale.

“Birinapant enabled the destruction of hepatitis B-infected liver cells while leaving normal cells unharmed. Excitingly, when birinapant was administered in combination with current antiviral drug entecavir, the infection was cleared twice as fast compared with birinapant alone. We are hopeful these promising results will be as successful in human clinical trials, which are currently underway in Melbourne, Perth and Adelaide,” said Pellegrini.

According to the World Health Organisation, more than 350 million people are affected by chronic hepatitis B, mostly in developing countries in sub-Saharan Africa and Asia. The disease can cause liver and kidney failure and cancer, and where they are affordable, retroviral drugs have to be taken for the patient’s entire lifetime, or until he or she can be given an organ transplant. More than 700,000 die from it each year.

Pellegrini said the drug restores apoptosis; a biological mechanism that clears damaged cells, which are affected by both, cancer and hepatitis.

“Normally, [healthy] liver cells would respond to infection by switching on a signal that tells the cell to destroy itself ‘for the greater good’, preventing further infection. However our research showed that the virus commandeers the liver cells’ internal communications, telling the cells to ignore the infection and stay alive. Birinapant flips the cell survival ‘switch’ used by the virus, causing the infected cell to die.”

The Australian team believes that targeting the cell, and not the virus itself, is not only more effective, but also avoids the emergence of drug-resistant strains of any virus, which is a growing danger.

“It is relatively easy for an organism to adapt to a drug, but it is very difficult to adapt to a change in the host cell. The virus relies on the survival mechanisms of the host, so if it can’t exploit them, it dies. Such a monumental change in the virus’ environment may be too big a hurdle for it to adapt to.”

Pellegrini believes birinapant and similar medicines could be used to combat numerous other illnesses.

“Pathogens that infect and reside inside host cells, including viral diseases such as HIV, herpes simplex and dengue fever, and bacterial infections such as tuberculosis, could all potentially be cured in a similar way,” he said.

Developed by mid-sized Pennsylvania company Tetralogic, birinapant has been undergoing medical tests since 2009, and is currently undergoing Phase II trials, meaning it is likely still several years away from hitting the shelves.

czezzt

看不懂。

tlyuhq

新的药物“百分之100成功”以前不能治愈乙型肝炎的治疗
发表时间：2015年4月22日19时53分
编辑时间：2015年4月24日08:28
澳大利亚科学家使用一种实验性癌症药物彻底治愈数百只老鼠患慢性乙型肝炎的治疗是现在正在进行试验的人，可以用于治疗疾病如艾滋病和耐药结核病。
“我们是百分之100的成功治疗HBV（乙型肝炎病毒）在临床前模型测试数百感染，说：”佩莱格里尼，谁LED在墨尔本的沃尔特和伊莱扎学院队，澳大利亚最古老的医学研究设施。
的团队，他们的研究结果发表在美国国家科学院院刊（PNAS）杂志本周，用birinapant，美国创造了治疗癌症的药物，并已进行超过350的美国人，但尚未上市销售。
“birinapant使乙肝病毒感染的肝细胞的破坏，而不伤害正常细胞。令人兴奋的是，当birinapant是当前抗病毒药物恩替卡韦联合管理，感染被清除birinapant单独比较快一倍。我们希望这些有希望的结果将在人体临床试验成功，这是目前在墨尔本，珀斯和阿德莱德，”佩莱格里尼说。
根据世界卫生组织的报告，超过350000000人是慢性乙型肝炎的影响，尤其是在撒哈拉以南的非洲和亚洲的发展中国家。这种疾病可以导致肝、肾衰竭和癌症，而他们负担得起的，逆转录病毒药物都要为病人的一生，直到他或她可以接受器官移植。超过700000，每年死于它。
佩莱格里尼说，恢复细胞凋亡的药物；生物机制，清除受损细胞，这是受，癌症和肝炎。
“通常情况下，[健康]肝细胞感染接通信号，告诉细胞自我毁灭的'为了伟大的善行”，防止进一步的感染。然而我们的研究表明，病毒能利用肝细胞的内部通信，告诉细胞忽略感染和活着。birinapant翻转病毒利用细胞存活的“开关”，导致感染细胞死亡。”
澳大利亚队认为靶向细胞，而不是病毒本身，不仅更有效，而且避免了任何病毒耐药菌株的产生，这是一个不断增长的危险。
“一个有机体适应药物是相对容易的，但它是适应宿主细胞的改变很难。病毒依赖于主机的生存机制，所以如果它不能利用他们，它死了。这样一个病毒的巨大变化的环境可能是它适应了太大的障碍。”
佩莱格里尼认为birinapant和类似的药物可用于作战的众多其他疾病。
“病原体感染存在于宿主细胞，包括病毒性疾病如艾滋病病毒，单纯疱疹病毒和登革热，肺结核等细菌感染，都可能会以类似的方式治愈，”他说。
宾夕法尼亚国内开发的中型公司，birinapant已经体检2009以来，目前正在进行II期临床试验，这意味着它是从上架可能还需要几年的时间。

三叠

给一下文章出处吧

三叠

读了一下论文摘要：

说得好像还是比较保守

只是说促进hbv清除。

不知道报道是哪家写的呢？

三叠

Significance

Hepatitis B virus (HBV) causes substantial morbidity and mortality. A large proportion of infected individuals controls infection but does not completely eradicate HBV DNA from the liver, and flares in hepatitis can be precipitated by immunosuppression. A proportion of individuals never controls infection, and these people are at substantial risk of developing liver failure and liver cancer. Current therapies are not effective at eliminating virus, and there is a major interest in developing functional cures for HBV infection. We identified host cell signaling molecules that can restrict the ability to eradicate infected cells. These molecules can be therapeutically targeted, and drugs that interfere with the function of these host cell proteins may be useful therapies to promote clearance of HBV infection.
Abstract

Hepatitis B virus (HBV) infection can result in a spectrum of outcomes from immune-mediated control to disease progression, cirrhosis, and liver cancer. The host molecular pathways that influence and contribute to these outcomes need to be defined. Using an immunocompetent mouse model of chronic HBV infection, we identified some of the host cellular and molecular factors that impact on infection outcomes. Here, we show that cellular inhibitor of apoptosis proteins (cIAPs) attenuate TNF signaling during hepatitis B infection, and they restrict the death of infected hepatocytes, thus allowing viral persistence. Animals with a liver-specific cIAP1 and total cIAP2 deficiency efficiently control HBV infection compared with WT mice. This phenotype was partly recapitulated in mice that were deficient in cIAP2 alone. These results indicate that antagonizing the function of cIAPs may promote the clearance of HBV infection.

http://www.pnas.org/content/112/18/5797.short

Livewellnyc

http://www.medicaldaily.com/hepatitis-b-infection-100-eliminated-cancer-drug-combination-preclinical-model-329938
http://rt.com/news/252129-hepatitis-drug-trial-australia/

是百分之百清除，不是促进清楚。澳大利亚墨尔本的沃特 霍尔研究院的marc pellegrini说，“我们在前期临床模型中是百分之百治愈乙肝病毒。
“We were 100 per cent successful in curing HBV (hepatitis B virus) infection in hundreds of tests in preclinical models,” said Marc Pellegrini, who led a team at Melbourne’s Walter and Eliza Hall Institute, Australia’s oldest medical research facility.

不过不幸的是这项研究与上个月暂停，原因是在第一组实验中发现有颅内神经麻痹的副作用。真正研发成功还需相当长的时间。不过丙肝彻底清除的药已经上市（Gilead的harvoni)，彻底治疗乙肝的药物应该只是时间问题。

疯一点好

到讨论版看看吧

zgct

基本黄了